Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
作者信息
Girard Sandrine, Lours Camille
机构信息
Laboratory of Hematology, Center of Biology and Pathology East, Hospices Civils de Lyon, Bron, France.
出版信息
Am J Hematol. 2023 Oct;98(10):1665-1666. doi: 10.1002/ajh.26969. Epub 2023 May 25.
PMID:37226864
Abstract
摘要
相似文献
1
Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
Am J Hematol. 2023 Oct;98(10):1665-1666. doi: 10.1002/ajh.26969. Epub 2023 May 25.
2
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
ESMO Open. 2021 Feb;6(1):100033. doi: 10.1016/j.esmoop.2020.100033. Epub 2021 Jan 11.
3
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Oncotarget. 2015 Sep 29;6(29):27490-504. doi: 10.18632/oncotarget.4748.
4
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Br J Haematol. 2023 May;201(3):e25-e29. doi: 10.1111/bjh.18766. Epub 2023 Mar 23.
5
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Blood Rev. 2021 Jan;45:100696. doi: 10.1016/j.blre.2020.100696. Epub 2020 May 7.
6
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18.
7
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Haematologica. 2013 Sep;98(9):1397-406. doi: 10.3324/haematol.2012.079251. Epub 2013 Jan 24.
8
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Haematologica. 2009 May;94(5):638-46. doi: 10.3324/haematol.2008.001933.
9
Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
Eur J Cancer. 2021 Nov;157:59-62. doi: 10.1016/j.ejca.2021.08.016. Epub 2021 Sep 3.
10
Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.
Blood Cancer J. 2022 Jan 25;12(1):11. doi: 10.1038/s41408-022-00607-7.
Zotero 插件